- Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds
- Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials
- The company intends to contribute to the growing body of research through academic collaborations with leading American institutions
- The research will focus on indications that other pharmaceutical companies have largely ignored
Although we can accurately describe the psychedelics industry as nascent, psychedelics have been the subject of a flurry of groundbreaking research that have gradually lifted the stigma surrounding their use. This ever-expanding body of research has proven the utility and efficacy of psychedelics in treating neuropsychiatric disease and improving mental health.
The research-backed revival of the interest in psychedelics has led to the emergence of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical developer founded in 2019, and other companies. Tryp focuses on producing novel bioscience solutions for conditions with unmet needs. Its current flagship program, Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”), involves the use of psychedelics. One of two drug development platforms, PFNTM targets chronic pain conditions, including fibromyalgia, and eating disorders, and its lead drug candidate is TRP-8802.
Tryp is leveraging existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 to proceed directly to Phase 2a clinical trials, in effect expediting drug development. The company is also looking to contribute to the ongoing research of psychedelics by collaborating with leading academic institutions. Already, Tryp has partnered with the University of Florida and lead investigator Jennifer Miller, M.D., for a Phase 2a clinical trial that will assess the efficacy and safety of TRP-8802 in treating eating disorders (https://ibn.fm/rV95K).
A professor of pediatrics and endocrinology, Miller has deep knowledge and expertise with eating disorders. In fact, as the director of the University of Florida Health’s Prader-Willi Syndrome (“PWS”) Program, she follows over 500 patients with PWS and more than 100 patients with early-onset obesity (https://ibn.fm/r9LVZ). Miller’s selection as the lead for the Phase 2a clinical trial is part of Tryp’s strategy to collaborate with principal investigators with deep understanding and knowledge of certain disease states.
“We’ve been building a number of partnerships in the academic front,” said Tryp Chairman and CEO Greg McKee during an interview with Steve Darling from Proactive (https://ibn.fm/akAAv). “We’ve announced our relationship with the University of Florida. We’ve got several others that are in the works. We’ve got a deep conversation with a very well-known institution in the Midwest that we’ll be announcing shortly, we believe, and also two other conversations that we’ll soon be able to reveal; one with a significant academic collaborator in Southern California and a second conversation with an academic institution up in Northern California.”
McKee described these institutions as having deep expertise in some particular fields, including two of the major areas Tryp is currently interested in: eating disorders (specifically hyperphagia, PWS, and binge eating) and chronic pain conditions (specifically fibromyalgia, complex regional pain syndrome, and phantom limb syndrome).
“What’s important to us is that these are indications that no other company, at least up to this point, is going after and again, there’s great unmet medical need here and, we believe, a lot of room for new novel treatments,” McKee continued.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
